



WELCOME!

THE COALITION AGAINST MAJOR DISEASES (CAMD)

Accelerating the Development and Review of Medical Products for Neurodegenerative Diseases

CAMD Annual Meeting and Regulatory Workshop

October 19, 2016

Stephen P Arnerić, Executive Director

Volker D Kern, Senior Project Manager

Jennifer Ashley E Ferstl, Project Coordinator




COALITION AGAINST MAJOR DISEASES (CAMD)



Mission

To develop, as a pre-competitive consortium, new technologies and methods to accelerate the development and review of medical products for treating Alzheimer's Disease and dementias of related neurodegenerative diseases.



Focus

Advancement of Drug Development Tools (DDTs) for Alzheimer's disease and related dementias with impaired cognition and function.

COALITION AGAINST MAJOR DISEASES (CAMD)



“Advancing science through cross-disciplinary collaboration”

CAMD
Teams/Working Groups:
Imaging Biomarker Team
Modeling & Simulation Team
CSF Biomarker Team
Digital Drug Development Tool Team
Informed Consent Working Group



Drug Development Tools for Alzheimer’s Disease and Related Dementias:
Common Data Standards
Integrated, Actionable Database
Quantitative Modeling
Biomarker Qualification

■ FDA ■ EMA ★ Letter of Support

Disease or Target	Drug Development Tools	Feasibility	Scope	Research	Submission	Qualification
Alzheimer’s Disease (AD)	Imaging Biomarkers	■	■	★	■	■
	CSF Biomarkers	■				
	Clinical Trial Simulator for Mild and Moderate AD	■	■	■	■	■
	Disease Model of MCI/aMCI	■	■			
	Biometric Monitoring Device (BMD) Assessments	■	■			

PATIENT DATA IS FOUNDATIONAL



Brian Van Buren was diagnosed with younger-onset Alzheimer's disease in 2015 at age 64.


C-PATH CLINICAL DATA CONTRIBUTIONS



Strong Foundation for Degenerative Diseases

Data contributed to C-Path

Clinical data: 83 studies
49,521 subjects



CAMD CLINICAL TRIAL SIMULATION TOOL (OCTOBER 10, 2016) (% change over the last 4 months)



CAMD'S CLINICAL TRIAL SIMULATION TOOL FOR ALZHEIMER'S DISEASE

58

Organizations

+7%

AstraZeneca

Biogen

Bristol-Myers Squibb

Lilly

Merck

Pfizer

Takeda

...and others

72

Individuals

+7%



18

Academic
Institutions

+13%



HARVARD
UNIVERSITY



Karolinska
Institutet



THE LONDON SCHOOL
OF ECONOMICS AND
POLITICAL SCIENCE

Imperial College
London



UNIVERSITY OF
FLORIDA

MANCHESTER
1824

The University of Manchester



Penn
UNIVERSITY OF PENNSYLVANIA



USC University of
Southern California

...and others

CAMD'S ALZHEIMER'S DISEASE DATABASE (OCTOBER 10, 2016) (% change over the last 4 months)



CAMD'S ALZHEIMER'S DISEASE DATABASE

242

+3%

Organizations

Abbott
ALSTDI
ALZFORUM
BILL & MELINDA GATES
foundation
GE Global Research
Genentech
GlaxoSmithKline
National Institutes of Health
The Michael J. Fox Foundation
...and others

343

+3%

Individuals



89

+3%

Academic
Institutions



...and others

DIGITAL DRUG DEVELOPMENT TOOLS



Qualifying Biometric Monitoring Devices (BMDs) for Specific Contexts-of-Use

WHAT

Data (signal output) collected from a biosensor that measures a biological response





HOW

Continuous physiological monitoring with devices (wearables/smart phones, clothing, implants/ingestible, remote biosensors)


WHY

Improve our understanding of real-time changes in **FUNCTION** during the progression of life in health & disease

I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning.



THE FUTURE OF SENSORS



FWD Health

Dashboard Tracks Exercise Regimes or Lowered Insurance Prices
www.fwdhealth.co

1. Passive data gathering
2. Meaningful interpretation
3. Internal sensors attached to body's organs

